DFX Intelligence
Borrowers
150 borrower groups currently held, grade A and BWhat a borrower group isA borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.
Industry as filed contains “Health Care Equipment” (remove)
Start from
150 borrower groups
| Borrower | Sponsor | BDCs | Principal held | On cost | Spread | Next maturity | First seen |
|---|---|---|---|---|---|---|---|
| Spruce Bidco II Inc Life sciences | unattributed | 10 | at least $772M | 100c | 2 pts | Jan 1, 2032 | Sep 30, 2024 |
| PerkinElmer U.S. LLC Life sciences | unattributed | 16 | at least $705M | 100c | 1 pts | Mar 1, 2029 | Mar 31, 2023 |
| BVI Medical, Inc Life sciences | unattributed | 11 | at least $548M | 87c | 10 pts | Mar 1, 2032 | Sep 30, 2022 |
| A•• G•••• H•••••••• I•• Life sciences | unattributed | 9 | at least $516M | 70c | n/a | Aug 1, 2027 | Dec 31, 2021 |
| Z••• C•••••• L•• Life sciences | unattributed | 7 | at least $428M | 94c | 7 pts | Feb 28, 2030 | Dec 31, 2023 |
| P••••• B•••• L•• Life sciences | Sponsor not establishedpossible: P••••• C•••••• P•••••••• I••• (a company of this name is on the sponsor's portfolio page) | 13 | at least $413M | 57c | 10 pts | Mar 1, 2027 | Dec 31, 2021 |
| P•••••• A••••••••• T•••• S•••••• Life sciences | unattributed | 6 | at least $337M | 100c | 1 pts | Jan 1, 2028 | Dec 31, 2021 |
| N•••••• P•••••••• L•• Life sciences | unattributed | 8 | at least $248M | 101c | 1 pts | Nov 1, 2030 | Dec 31, 2021 |
| G••• B•••• I•• Life sciences | unattributed | 3 | at least $216M | 101c | 2 pts | Oct 1, 2031 | Dec 31, 2024 |
| O••• B•••••••• L•• Life sciences | unattributed | 13 | at least $205M | 100c | 2 pts | Apr 26, 2029 | Dec 31, 2021 |
| C•••••• L•• Life sciences · grade B | unattributed | 1 | at least $188M | 100c | n/a | Jun 18, 2029 | Jun 30, 2024 |
| P••••••••• Life sciences | unattributed | 1 | at least $185M | 102c | n/a | Oct 15, 2032 | Dec 31, 2025 |
| P••• L•• Life sciences | Sponsor not establishedpossible: G•••••• C•••••• (a company of this name is on the sponsor's portfolio page) | 6 | at least $178M | 100c | 0 pts | Mar 1, 2028 | Dec 31, 2021 |
| H••••••• I•• Life sciences | unattributed | 10 | at least $173M | 99c | 2 pts | Apr 1, 2033 | Sep 30, 2025 |
| V•••••• S••••• B•••• I• I•• Life sciences | unattributed | 1 | at least $147M | 100c | n/a | Jan 30, 2032 | Mar 31, 2025 |
| C•••••• A••••••••• L•• Life sciences | unattributed | 7 | at least $135M | 94c | 14 pts | Oct 11, 2029 | Dec 31, 2022 |
| H••••••• T•••••• I•• Life sciences | unattributed | 3 | at least $110M | 102c | 2 pts | Nov 28, 2031 | Sep 30, 2024 |
| A••••••• V••••• P••••••• Life sciences | Sponsor not establishedpossible: H••••• C••••••• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $101M | 100c | 0 pts | Sep 1, 2026 | Dec 31, 2021 |
| E••••••••• L••• H••••••• I•• Life sciences | Sponsor not establishedpossible: M••••• A•••• M••••••••• L• (a company of this name is on the sponsor's portfolio page) | 2 | at least $97.2M | 100c | 0 pts | Apr 30, 2031 | Sep 30, 2022 |
| H•••••••• B••••• I•• Life sciences | unattributed | 5 | at least $92.7M | 100c | 1 pts | Sep 29, 2027 | Dec 31, 2024 |
| A•• H••••••• I• C••• Life sciences | unattributed | 6 | at least $88.8M | 90c | 0 pts | Feb 1, 2028 | Sep 30, 2022 |
| Y•• L•• Life sciences | Sponsor not establishedpossible: L••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 17 | at least $88.1M | 100c | 2 pts | Dec 1, 2029 | Dec 31, 2021 |
| R••••••••• L•• Life sciences | unattributed | 15 | at least $87.4M | 100c | 0 pts | Jun 1, 2031 | Dec 31, 2021 |
| T••• L••••• P•••••••• I•• Life sciences | unattributed | 15 | at least $84.2M | 100c | 2 pts | Dec 1, 2029 | Dec 31, 2023 |
| I•• H••••• M••••• S••• I•• Life sciences | Sponsor not establishedpossible: L••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 3 | at least $75.7M | 102c | 3 pts | Jun 7, 2030 | Jun 30, 2024 |
| A••••••• B••••• I•• Life sciences | unattributed | 4 | at least $73.3M | 101c | 0 pts | Mar 12, 2031 | Dec 31, 2023 |
| H•••••• C••• B••••• I•• Life sciences | Sponsor not establishedpossible: B•••••••• E••••• P••••••• L•• (a company of this name is on the sponsor's portfolio page) | 3 | at least $73.3M | 101c | 0 pts | Mar 31, 2028 | Dec 31, 2021 |
| D••••• C••• A••••••• I•• Life sciences | unattributed | 3 | at least $73.1M | 101c | n/a | Jun 1, 2031 | Dec 31, 2021 |
| R••••••••• M••••••• L•• Life sciences | unattributed | 4 | at least $68.9M | 100c | 0 pts | Jun 21, 2027 | Sep 30, 2022 |
| C••• B••••••• L•• Life sciences | unattributed | 9 | at least $61.4M | 100c | 0 pts | Apr 29, 2033 | Sep 30, 2022 |
| O••••••• G•••• H•••••••• I•• Life sciences | Sponsor not establishedpossible: H••••• C••••••• L•• (a company of this name is on the sponsor's portfolio page) | 12 | at least $54.9M | 100c | 1 pts | May 1, 2031 | Dec 31, 2021 |
| P•••••••• H••• R••••••••• S•••••••• L•• Life sciences | unattributed | 7 | at least $54.8M | 99c | 1 pts | Dec 23, 2030 | Dec 31, 2022 |
| A••••••• D••••••••• • C••••••• S•••••• Life sciences | unattributed | 4 | at least $53.7M | 93c | 1 pts | Aug 1, 2026 | Dec 31, 2021 |
| S•• C•••• Life sciences | unattributed | 1 | at least $51.4M | 97c | n/a | Oct 24, 2032 | Dec 31, 2025 |
| E•••• P•••••••• L•• Life sciences | unattributed | 2 | at least $50.7M | 92c | 0 pts | Dec 6, 2027 | Dec 31, 2022 |
| S••••• G•••• H•••••••• L•• Life sciences | unattributed | 7 | at least $49.5M | 101c | 1 pts | Jun 16, 2027 | Dec 31, 2021 |
| A•••••••• I•• Life sciences | unattributed | 3 | at least $49.5M | 101c | 1 pts | Jan 1, 2031 | Mar 31, 2024 |
| M••••• A••••••••• C••• Life sciences | unattributed | 4 | at least $46.0M | 101c | 2 pts | Oct 1, 2027 | Sep 30, 2023 |
| A••••••••• C••• I•• Life sciences | unattributed | 5 | at least $45.4M | 101c | 1 pts | Jun 1, 2031 | Dec 31, 2020 |
| D•••••• H•••••••• L•• Life sciences · grade B | unattributed | 1 | at least $43.6M | 20c | n/a | Feb 4, 2027 | Sep 30, 2022 |
| M•••••• G•••••••• L•• Life sciences | unattributed | 2 | at least $43.4M | 101c | 1 pts | Apr 26, 2028 | Mar 31, 2022 |
| E••••••• I•••••••• I•• Life sciences | unattributed | 3 | at least $41.2M | 81c | 5 pts | Jun 28, 2029 | Sep 30, 2022 |
| O•• C••• C••• M••••••••• I•• Life sciences | unattributed | 1 | at least $40.9M | 103c | n/a | May 1, 2032 | Dec 31, 2020 |
| E•• S••••••• I•• Life sciences | Sponsor not establishedpossible: B••••• W••• C••••••• L•• (a company of this name is on the sponsor's portfolio page) | 1 | at least $40.0M | 101c | n/a | Jun 15, 2027 | Dec 31, 2022 |
| G•••• R•••• A•••••• M••••••••• I•• Life sciences | Sponsor not establishedpossible: A•••••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 3 | at least $38.5M | 99c | 1 pts | Mar 10, 2031 | Sep 30, 2024 |
| G•••••• L•• Life sciences · grade B | unattributed | 1 | at least $38.2M | 79c | n/a | Feb 1, 2027 | Sep 30, 2022 |
| R•••• 9• M••••••• I•• Life sciences | Sponsor not establishedpossible: I••••••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 1 | at least $35.0M | 101c | n/a | Mar 31, 2029 | Dec 31, 2022 |
| B••••••••• A•••••••• I•• Life sciences | unattributed | 1 | at least $33.9M | 100c | n/a | May 31, 2033 | Jun 30, 2026 |
| O•••••••• H•••••••• I•• Life sciences | unattributed | 1 | at least $31.4M | 56c | n/a | Jul 31, 2026 | Dec 31, 2022 |
| D•••••••• H•••••• I•• Life sciences | unattributed | 3 | at least $30.7M | 101c | 1 pts | Nov 1, 2030 | Dec 31, 2024 |
Page 1 of 3Next
The borrower, lender and sponsor names past the first 3 rows are hidden. Open a row to reveal that record with a free account (5 a month), or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source is public either way.